7JK logo

EQL Pharma DB:7JK Stock Report

Last Price

€5.62

Market Cap

€167.4m

7D

-2.1%

1Y

163.8%

Updated

04 Nov, 2024

Data

Company Financials +

7JK Stock Overview

Engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe.

7JK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance1/6
Financial Health3/6
Dividends0/6

EQL Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EQL Pharma
Historical stock prices
Current Share PriceSEK 5.62
52 Week HighSEK 5.88
52 Week LowSEK 2.12
Beta0.73
11 Month Change11.07%
3 Month Change25.73%
1 Year Change163.85%
33 Year Change85.48%
5 Year Changen/a
Change since IPO60.57%

Recent News & Updates

Recent updates

Shareholder Returns

7JKDE HealthcareDE Market
7D-2.1%-1.9%-1.8%
1Y163.8%24.7%13.6%

Return vs Industry: 7JK exceeded the German Healthcare industry which returned 24.7% over the past year.

Return vs Market: 7JK exceeded the German Market which returned 13.6% over the past year.

Price Volatility

Is 7JK's price volatile compared to industry and market?
7JK volatility
7JK Average Weekly Movement4.9%
Healthcare Industry Average Movement3.7%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7JK has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 7JK's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200622Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

EQL Pharma AB (publ) Fundamentals Summary

How do EQL Pharma's earnings and revenue compare to its market cap?
7JK fundamental statistics
Market cap€167.38m
Earnings (TTM)€2.26m
Revenue (TTM)€24.99m

74.1x

P/E Ratio

6.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7JK income statement (TTM)
RevenueSEK 290.75m
Cost of RevenueSEK 164.92m
Gross ProfitSEK 125.84m
Other ExpensesSEK 99.54m
EarningsSEK 26.29m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)0.90
Gross Margin43.28%
Net Profit Margin9.04%
Debt/Equity Ratio74.7%

How did 7JK perform over the long term?

See historical performance and comparison